← Back to Search

Tyrosine Kinase Inhibitor

Active for Non-Small Cell Lung Cancer (RAIN Trial)

Phase 2
Waitlist Available
Led By Stephen V Liu, MD
Research Sponsored by Rain Therapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 10 months.
Awards & highlights
No Placebo-Only Group

Summary

Open-label, Phase 2, single treatment arm, 3 cohorts

Eligible Conditions
  • Breast Cancer
  • Lung Cancer
  • Non-Small Cell Lung Cancer
  • Epidermal Growth Factor Receptor Mutations
  • ERBB Fusion

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 10 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 10 months. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
ORR

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: ActiveExperimental Treatment1 Intervention
tarloxotinib bromide

Find a Location

Who is running the clinical trial?

Rain Therapeutics Inc.Lead Sponsor
4 Previous Clinical Trials
241 Total Patients Enrolled
Rain Oncology IncLead Sponsor
8 Previous Clinical Trials
278 Total Patients Enrolled
Stephen V Liu, MDPrincipal InvestigatorGeorgetown University
~6 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top